- More than half of patients with migraine who were prescribed a first-line triptan for treatment did not refill their prescription within 12 months.
- Among those who did not refill their initial triptan prescription, more than half filled ≥1 opioid prescription in 24 months of follow-up and one-third filled a prescription for NSAIDs.
Why this matters
- Triptans are the standard recommended first-line treatment for moderate or severe migraines.
- Study of 10,509 patients (age ≥18 years) with ≥1 triptan prescription during 2013.
- Funding: Allergan, plc., Dublin, Ireland.
- 50.8% and 43.6% patients had no triptan refills over the 12 and 24 months, respectively.
- At 12- and 24-month postindex, respectively:
- 90.5% and 86.1% used 1 type of triptan;
- 8.4% and 12.0% used 2 different triptans;
- 1.0% and 2.0% used ≥3 different triptans.
- Among patients with no refill, commonly used acute medications:
- Opioids (39%) and NSAIDs (22%) at 12 months;
- Opioid (53%), NSAID (33%) at 24 months.
- At 24 months, patients with and without a triptan refill had similar use of:
- Opioids (39% vs 42%);
- NSAIDs (22% vs 22%);
- Butalbital (9% vs 10%).
- Retrospective study design.
Coauthored with Vijay Rathod, PhD.